# US 2004/0082052 A1 · Crystal structure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082052 A1
- Document ID: US20040082052A1
- Status: Published application
- Kind: A1
- Application number: 10/427,222
- Filed: 2003-05-01
- Published: 2004-04-29
- Earliest claimed: 2002-10-24
- Assignees: Pfizer Inc.
- Inventors: David Graham Brown; Colin Roger Groom; Andrew Lee Hopkins; Timothy Mark Jenkins; Sarah Helen Kamp; Margaret Mary O'Gara; Heather Joan Ringrose; Colin Mark Robinson; Wendy Elaine Taylor
- Web page: https://patentgrep.com/patent/US20040082052A1

## CPC

- C12N 9/16: acting on ester bonds (3.1)
- A61K 31/00: Medicinal preparations containing organic active ingredients
- C12Q 1/44: involving esterase
- C12Y 301/04035: 3',5'-Cyclic-GMP phosphodiesterase (3.1.4.35)
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to the soakable crystal structures of a phosphodiesterase 5 (PDE5) and their uses in identifying PDE5 ligands, including PDE5 inhibitor compounds. The present invention also relates to methods of identifying such PDE5 inhibitor compounds and their medical use. The present invention additionally relates to crystals of PDE5 into which ligands may be soaked and crystals of PDE5 comprising PDE5 ligands that have been soaked into the crystal.

## Claims

### Claim 1

A crystal of phosphodiesterase 5 (PDE5).

### Claim 2 (depends on 1)

The crystal of PDE5 according to claim 1, wherein the crystal is soakable.

### Claim 3 (depends on 1, 2)

The crystal of PDE5 according to any one of claims 1 or 2, wherein said PDE5 is from a mammal.

### Claim 4 (depends on 1, 2, 3)

The crystal of PDE5 according to any one of claims 1 to 3, wherein said PDE5 is from a human.

### Claim 5 (depends on 1, 2, 3, 4)

The crystal of PDE5 according to any one of claims 1 to 4, wherein said PDE5 is an isoform selected from the group including PDE5A1, PDE5A2, PDE5A3 and PDE5A4.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The crystal of PDE5 according to any one of claims 1 to 5, wherein said PDE5 comprises SEQ ID NO: 1 or a homologue, fragment, variant, analogue or derivative thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The crystal of PDE5 according to any one of claims 1 to 6, wherein said PDE5 comprises SEQ ID NO: 4 or a homologue, fragment, variant, analogue or derivative thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The crystal of PDE5 according to any one of claims 1 to 7, wherein said PDE5 comprises SEQ ID NO: 5 or a homologue, fragment, variant, analogue or derivative thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The crystal of PDE5 according to any one of claims 1 to 8, wherein said PDE5 comprises SEQ ID NO: 6 or a homologue, fragment, variant, analogue or derivative thereof.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The crystal of PDE5 according to any one of the claims 1 to 9 which is grown using polyethylene glycol as a precipitant.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The crystal of PDE5 according to any one of claims 1 to 10 which is grown in a buffer in the pH range of 6.5 to 8.0.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The crystal of PDE5 according to any one of the claims 1 to 11 which is grown in the presence of an alcohol.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The crystal of PDE5 according to any one of the claims 1 to 12 which is grown in a solution containing HEPES buffer, polyethylene glycol 4000 and iso-propanol.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The crystal of PDE5 as defined in any one of claims 1 to 13, which has one or more of the following characteristics:
(g) a space group C2;
(h) unit cell dimensions a˜56 Å±1%, b˜77 Å±1%, c˜81 Å±1%, α=γ=90°, β=103°±1%;
(i) 1 molecule per asymmetric unit;
(J) comprises a PDE5 of a molecular weight of approximately 4 OkDa±2 kDa;
(k) a calculated solvent content of approximately 47±5%; and
(1) a monoclinic crystal system.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The crystal of PDE5 as claimed in any one of claims 1 to 14, wherein PDE5 has an active site within the third sub-domain of the protein which is bounded by Helices 15 (H15 813-824) and 14 (H14 772-797), the C-terminus of Helix 13 (H13 749-25 765), and the C-terminus of Helix 11 (H11 706-721) along with the loop region between Helices 11 and 12a (H12a 725-731) as shown in FIG. 2.

### Claim 16 (depends on 15)

The crystal of PDE5 as claimed in claim 15, wherein the active site is capable of accommodating a pyrazolo-pyrimidinone.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The crystal of PDE5 as claimed in any one of the claims 1 to 16, wherein PDE5 has an active site within the third sub-domain of the protein and comprises Leu 765, Ala 767 and Ile 768 and one or more of Phe 820, Val 782, Phe 786, Tyr 612, Leu 804, Ala 779, Ala 783, Ile 813, Met 816 and Gln 817.

### Claim 18 (depends on 17)

The crystal of PDE5 as claimed in claim 17, wherein the active site is capable of accommodating a ligand or inhibitor.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The crystal of PDE5 as claimed in any one of the claims 1 to 18, wherein said PDE5 has a three-dimensional structure characterised by the atomic co-ordinates set out in Table 4 or a derivative set as expressed in any reference frame.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A heavy atom derivative of the crystal of PDE5 as claimed in any one of the claims 1 to 19.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The crystal of PDE5 as claimed in any one of claims 1 to 20, wherein a PDE5 ligand has been soaked in.

### Claim 22 (depends on 22)

The crystal of PDE5 as claimed in claim 22, wherein said PDE5 ligand is a PDE5 inhibitor.

### Claim 23 (depends on 22)

The crystal of PDE5 as claimed in claim 22, wherein said PDE5 inhibitor is a pyrazolo-pyrimidinone.

### Claim 24 (depends on 21, 22, 23)

The crystal of PDE5 as claimed in any one of claims 21 to 23, wherein said PDE5 has a three-dimensional structure characterised by the atomic co-ordinates set out in Table 5 or a derivative set as expressed in any reference frame.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of the atomic co-ordinates determined from the crystal of PDE5 according to any one of claims 1 to 24 for deriving a three-dimensional structure of a PDE5 or a mutant, derivative, variant, analogue, homologue, sub-domain or fragment thereof.

### Claim 26 (depends on 25)

Use according to claim 25, wherein the PDE5 sub-domain is the catalytic domain.

### Claim 27 (depends on 25, 26)

Use of the three-dimensional structure of PDE5 as derivable according to one of claim 25 or claim 26 to computationally or otherwise evaluate the binding interactions of a chemical compound with an active site on PDE5.

### Claim 28 (depends on 27)

Use of the three-dimensional structure of PDE5 as derivable according to claim 27 to design a compound capable of associating with PDE5.

### Claim 29 (depends on 27, 28)

Use according to claim 27 or claim 28, wherein the compound is a PDE5 ligand.

### Claim 30 (depends on 29)

Use according to claim 29, wherein said compound is a PDE5 inhibitor.

### Claim 31 (depends on 30)

Use according to claim 30, wherein said PDE5 inhibitor is a pyrazolo-pyrimidinone.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method of selecting a compound capable of associating with PDE5 from a group of potential PDE5 ligand compounds comprising the following steps:
i. soaking the crystal of PDE5 according to any one of claims 1 to 19 in a solution containing a potential PDE5 ligand compound;
ii. determining the three-dimensional structure from the soaked crystal; and
iii. assessing whether the compound is bound to PDE5.

### Claim 33 (depends on 32)

A compound selected by the use according to claim 32.

### Claim 34 (depends on 28, 29, 30, 31, 32)

A compound designed by the use according to any one of claims 28 to 31 or identified by the method of claim 32.

### Claim 35 (depends on 34)

The compound according to claim 34, which is a PDE5 inhibitor.

### Claim 36 (depends on 25, 26)

A method of selecting a PDE5 ligand from a group of potential PDE5 ligands, comprising the following steps:
(a) computationally creating a three-dimensional representation of the structure of 30 PDE5 as derivable according to any one of claim 25 or claim 26, and a three-dimensional representation of the structure of the potential PDE5 ligand;
(b) co-displaying the three-dimensional representation of the potential PDE5 ligand with the three-dimensional representation of the PDE5 structure; and
(c) assessing whether the three-dimensional representation of the potential PDE5 ligand fits the three-dimensional representation of an active site of the PDE5 structure.

### Claim 37 (depends on 36)

The method according to claim 36, further comprising the following steps:
(d) incorporating the potential PDE5 ligand in a biological PDE5 activity assay; and
(e) determining whether the potential PDE5 ligand modulates PDE5 activity in said assay.

### Claim 38 (depends on 36, 37)

The method according to any one of claim 36 or claim 37 wherein said potential PDE5 ligand is a potential PDE5 inhibitor compound and said potential PDE5 inhibitor compound inhibits PDE5 activity.

### Claim 39 (depends on 36, 37, 38)

A PDE5 ligand selected by the method of any one of claims 36 to 38.

### Claim 40 (depends on 39)

Use of a PDE5 ligand according to claim 39 as a pharmaceutical.

### Claim 41 (depends on 39)

A pharmaceutical composition comprising one or more PDE5 ligands according to claim 39 and one or more pharmaceutically acceptable excipients.

### Claim 42 (depends on 39)

Use of a PDE5 ligand according to claim 39 in the manufacture of a medicament for the prophylaxis or treatment of a condition, disease, disorder or dysfunction where the inhibition of PDE5 is prophylactically or therapeutically beneficial.

### Claim 43 (depends on 42)

Use according to claim 42, wherein said disorder is a mammalian sexual disorder.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of the atomic co-ordinates determined from the crystal of PDE5 according to any one of claims 1 to 24, to solve the crystal structure of a mutant, derivative, fragment, variant, analogue, homologue or complex of PDE5.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of the atomic co-ordinates determined from the crystal of PDE5 according to any one of claims 1 to 24, to produce a model of the three-dimensional structure of PDE5-related proteins.

### Claim 46 (depends on 25, 26)

Use of the three-dimensional structure of PDE5 as derivable according to any one of claim 25 or claim 26 to design site-directed mutants that mimic other PDE5 isoforms or variants thereof.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method of soaking a chemical compound into a crystal according to any one of claims 1 to 20 comprising the following steps:
a) incubating the crystal in an aqueous stabilising solution comprising buffer lo and polyethylene glycol;
b) combining the chemical compound with the stabilising solution; and
c) optionally adding a cryo-protectant to the stabilising solution.
